Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nico J. Meeuwenoord is active.

Publication


Featured researches published by Nico J. Meeuwenoord.


Organic Letters | 2010

Synthesis of oligoribonucleic acid conjugates using a cyclooctyne phosphoramidite.

Pieter van Delft; Nico J. Meeuwenoord; Sascha Hoogendoorn; Jasper Dinkelaar; Herman S. Overkleeft; Gijsbert A. van der Marel; Dmitri V. Filippov

The conjugation of a ribonucleic acid 16-mer with the cationic amphiphilic peptide penetratin and an anionic hyaluronan tetrasaccharide by means of Cu-free click chemistry is reported. The alkyne-functionalized 16-mer was prepared by automated solid-phase synthesis, using a newly developed strained cyclooctyne phosphoramidite in the final coupling. Cycloaddition of the alkyne functionalized RNA to the azide containing biomolecules led to a clean conversion into the corresponding nucleic acid conjugates.


Tetrahedron Letters | 1999

DESIGN AND SYNTHESIS OF A PROTEIN:FARNESYLTRANSFERASE INHIBITOR BASED ON SUGAR AMINO ACIDS

Herman S. Overkleeft; Steven H. L. Verhelst; Elsbet J. Pieterman; Nico J. Meeuwenoord; Mark Overhand; Louis H. Cohen; Gijs A. van der Marel; Jacques H. van Boom

Abstract The synthesis of four partially deoxygenated gluconic amino acids from fully acetylated D-glucal is described. Replacement of the central AA dipeptide in the CAAX tetrapeptide corresponding to the C-terminus of K-Ras p21 by one of these sugar amino acid building blocks led to a novel protein:farnesyl transferase inhibitor.


Cancer immunology research | 2014

Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates

Gijs G. Zom; Selina Khan; Cedrik M. Britten; Vinod Sommandas; Marcel Camps; Nikki M. Loof; Christina F. Budden; Nico J. Meeuwenoord; Dmitri V. Filippov; Gijsbert A. van der Marel; Hermen S. Overkleeft; Cornelis J. M. Melief; Ferry Ossendorp

Zom, Khan, Britten, and colleagues report that direct conjugation of lipopeptide Pam3CSK4 to synthetic long peptides enhanced in vivo targeting and maturation of the conjugate with superior priming of CD8+ and CD4+ T cells in two mouse tumor models. Chemical conjugates comprising synthetic Toll-like receptor ligands (TLR-L) covalently bound to antigenic synthetic long peptides (SLP) are attractive vaccine modalities, which can induce robust CD8+ T-cell immune responses. Previously, we have shown that the mechanism underlying the power of TLR-L SLP conjugates is improved delivery of the antigen together with a dendritic cell activation signal. In the present study, we have expanded the approach to tumor-specific CD4+ as well as CD8+ T-cell responses and in vivo studies in two nonrelated aggressive tumor models. We show that TLR2-L SLP conjugates have superior mouse CD8+ and CD4+ T-cell priming capacity compared with free SLPs injected together with a free TLR2-L. Vaccination with TLR2-L SLP conjugates leads to efficient induction of antitumor immunity in mice challenged with aggressive transplantable melanoma or lymphoma. Our data indicate that TLR2-L SLP conjugates are suitable to promote integrated antigen-specific CD8+ and CD4+ T-cell responses required for the antitumor effects. Collectively, these data show that TLR2-L SLP conjugates are promising synthetic vaccine candidates for active immunotherapy against cancer. Cancer Immunol Res; 2(8); 756–64. ©2014 AACR.


Journal of Organic Chemistry | 2008

Synthesis of Sugar Nucleotides by Application of Phosphoramidites

Henrik Gold; Pieter van Delft; Nico J. Meeuwenoord; Jeroen D. C. Codée; Dmitri V. Filippov; Gerrit Eggink; Herman S. Overkleeft; Gijs A. van der Marel

A new method for the construction of pyrophosphates is reported based on the coupling of a sugar phosphate and a nucleoside phosphoramidite. The in situ formed phosphate-phosphite intermediate was subsequently oxidized with tBuOOH. Three UDP-N-acetylglucosamine derivatives were prepared using this one-pot procedure in good yields.


Angewandte Chemie | 2015

Synthesis of Well-Defined Adenosine Diphosphate Ribose Oligomers†

Hans A. V. Kistemaker; Lucien N. Lameijer; Nico J. Meeuwenoord; Herman S. Overkleeft; Gijsbert A. van der Marel; Dmitri V. Filippov

The post-translational modification of proteins that is known as adenosine diphosphate ribosylation (ADPr) regulates a wide variety of important biological processes, such as DNA-damage repair and cellular metabolism. This modification is also involved in carcinogenesis and the process of aging. Therefore, a better understanding of the function of ADP-ribosylation is crucial for the development of novel therapeutics. To facilitate the elucidation of the biology of ADPr, the availability of well-defined fragments of poly(ADP-ribose) is essential. Herein we report a solid-phase synthetic approach for the preparation of ADP-ribose oligomers of exactly defined length. The methodology is exemplified by the first reported synthesis of an ADP-ribose dimer and trimer.


PLOS ONE | 2010

Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG

Jasper G. van den Boorn; Debby Konijnenberg; Esther P. M. Tjin; Daisy I. Picavet; Nico J. Meeuwenoord; Dmitri V. Filippov; J.P. Wietze van der Veen; Jan D. Bos; Cornelis J. M. Melief; Rosalie M. Luiten

Background Presently melanoma still lacks adequate treatment options for metastatic disease. While melanoma is exceptionally challenging to standard regimens, it is suited for treatment with immunotherapy based on its immunogenicity. Since treatment-related skin depigmentation is considered a favourable prognostic sign during melanoma intervention, we here aimed at the reverse approach of directly inducing vitiligo as a shortcut to effective anti-melanoma immunity. Methodology and Principal Findings We developed an effective and simple to use form of immunotherapy by combining the topical skin-bleaching agent monobenzone with immune-stimulatory imiquimod cream and cytosine-guanine oligodeoxynucleotides (CpG) injections (MIC therapy). This powerful new approach promptly induced a melanoma antigen-specific immune response, which abolished subcutaneous B16.F10 melanoma growth in up to 85% of C57BL/6 mice. Importantly, this regimen induced over 100 days of tumor-free survival in up to 60% of the mice, and forcefully suppressed tumor growth upon re-challenge either 65- or 165 days after MIC treatment cessation. Conclusions MIC therapy is effective in eradicating melanoma, by vigilantly incorporating NK-, B- and T cells in its therapeutic effect. Based on these results, the MIC regimen presents a high-yield, low-cost and simple therapy, readily applicable in the clinic.


Journal of Biological Chemistry | 2006

Characterization of the DNA Binding and Structural Properties of the BRCT Region of Human Replication Factor C p140 Subunit

Masakazu Kobayashi; Francis Figaroa; Nico J. Meeuwenoord; Lars E. T. Jansen; Gregg Siegal

BRCT domains, present in a large number of proteins that are involved in cell cycle regulation and/or DNA replication or repair, are primarily thought to be involved in protein-protein interactions. The large (p140) subunit of replication factor C contains a sequence of ∼100 amino acids in the N-terminal region that binds DNA and is distantly related to known BRCT domains. Here we show that residues 375-480, which include 28 amino acids N-terminal to the BRCT domain, are required for 5′-phosphorylated double-stranded DNA binding. NMR chemical shift analysis indicated that the N-terminal extension includes an α-helix and confirmed the presence of a conserved BRCT domain. Sequence alignment of the BRCT region in the p140 subunit of replication factor C from various eukaryotes has identified very few absolutely conserved amino acid residues within the core BRCT domain, whereas none were found in sequences immediately N-terminal to the BRCT domain. However, mapping of the limited number of conserved, surface-exposed residues that were found onto a homology model of the BRCT domain, revealed a clustering on one side of the molecular surface. The cluster, as well as a number of amino acids in the N-terminal α-helix, were mutagenized to determine the importance for DNA binding. To ensure minimal structural changes because of the introduced mutations, proteins were checked using one-dimensional 1H NMR and CD spectroscopy. Mutation of weakly conserved residues on one face of the N-terminal α-helix and of residues within the cluster disrupted DNA binding, suggesting a likely binding interface on the protein.


Journal of Biological Chemistry | 2002

Site-specific Interactions of JBP with Base and Sugar Moieties in Duplex J-DNA EVIDENCE FOR BOTH MAJOR AND MINOR GROOVE CONTACTS

Robert Sabatini; Nico J. Meeuwenoord; Jacques H. van Boom; Piet Borst

β-d-Glucosyl-hydroxymethyluracil, also called base J, is an unusually modified DNA base conserved among Kinetoplastida. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes. We have previously identified a J-binding protein (JBP) in Trypanosoma, Leishmania, andCrithidia, and we have shown that it is a structure-specific binding protein. Here we examine the molecular interactions that contribute to recognition of the glycosylated base in synthetic DNA substrates using modification interference, modification protection, DNA footprinting, and photocross-linking techniques. We find that the two primary requirements for J-DNA recognition include contacts at base J and a base immediately 5′ of J (J-1). Methylation interference analysis indicates that the requirement of the base at position J-1 is due to a major groove contact independent of the sequence. DNA footprinting of the JBP·J-DNA complex with 1,10-phenanthroline-copper demonstrates that JBP contacts the minor groove at base J. Substitution of the thymine moiety of J with cytosine reduces the affinity for JBP ∼15-fold. These data indicate that the sole sequence dependence for JBP binding may lie in the thymine moiety of base J and that recognition requires only two specific base contacts, base J and J-1, within both the major and minor groove of the J-DNA duplex.


European Journal of Organic Chemistry | 2001

Chemical and Enzymatic Synthesis of DNA Fragments Containing 5-(β-D-Glucopyranosyloxymethyl)-2′-deoxycytidine − a Modified Nucleoside in T4 Phage DNA

Martin de Kort; Peter C. de Visser; Jürgen Kurzeck; Nico J. Meeuwenoord; Gijs A. van der Marel; Wolfgang Rüger; Jacques H. van Boom

DNA fragments 23 and 25, containing 5-hydroxymethyl-2′-deoxycytidine (5-HMdC) and 5-(β-D-glucopyranosyloxymethyl)-2′-deoxycytidine (5-GlcMdC) units, respectively, were assembled by means of a solid support-assisted synthesis using phosphoramidite building blocks 4 and 5, respectively. In addition, 20-mer 23 was converted into fragment 26 by a glycosylation with uridine diphosphoglucose (UDPG), catalyzed by T4 β-glucosyltransferase (BGT).


Leukemia | 2016

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

Guillem Soriano; Lenka Besse; Nan Li; Marianne Kraus; Andrej Besse; Nico J. Meeuwenoord; J Bader; B Everts; H den Dulk; Herman S. Overkleeft; Bogdan I. Florea; Christoph Driessen

Adaptive resistance of myeloma to proteasome inhibition represents a clinical challenge, whose biology is poorly understood. Proteasome mutations were implicated as underlying mechanism, while an alternative hypothesis based on low activation status of the unfolded protein response was recently suggested (IRE1/XBP1-low model). We generated bortezomib- and carfilzomib-adapted, highly resistant multiple myeloma cell clones (AMO-BTZ, AMO-CFZ), which we analyzed in a combined quantitative and functional proteomic approach. We demonstrate that proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition, irrespective of a proteasome mutation, and uniformly show an IRE1/XBP1-low signature. Adaptation of myeloma cells to proteasome inhibitors involved quantitative changes in >600 protein species with similar patterns in AMO-BTZ and AMO-CFZ cells: proteins involved in metabolic regulation, redox homeostasis, and protein folding and destruction were upregulated, while apoptosis and transcription/translation were downregulated. The quantitatively most upregulated protein in AMO-CFZ cells was the multidrug resistance protein (MDR1) protein ABCB1, and carfilzomib resistance could be overcome by MDR1 inhibition. We propose a model where proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition owing to metabolic adaptations that favor the generation of reducing equivalents, such as NADPH, which is supported by oxidative glycolysis. Proteasome inhibitor resistance may thus be targeted by manipulating the energy and redox metabolism.

Collaboration


Dive into the Nico J. Meeuwenoord's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ferry Ossendorp

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge